Healthcare operations

New CRISPR technology has demonstrated the ability to selectively destroy resistant cancer cells, including ‘undruggable’ types, marking a significant step in cancer therapy.

• Thorsten Meyer
• July 24, 2026

TransMedics will release its second quarter 2026 financial results on August 4, 2026, with analysts and investors awaiting the report’s details on company performance.

• This Info Team
• July 22, 2026

MaxCyte announces a multi-platform technology licensing partnership with Genentech to accelerate cell therapy development, expanding collaborative capabilities.

• This Info Team
• July 21, 2026

South Korea’s regulatory agency retains conditional approval for Neuronata-R, a key development for its market access and future commercialization.

• This Info Team
• July 20, 2026

A new pilot program tests daily postpartum check-ins for first-time mothers at home, aiming to improve recovery and reduce risks after birth.

• Thorsten Meyer
• July 19, 2026

4DMT announced positive two-year data from its PRISM Phase 2b clinical trial in a broad wet AMD population, showing promising efficacy results.

• This Info Team
• July 19, 2026

Harmony Biosciences announced an executive change through an SEC 8-K filing, signaling leadership updates at the company.

• This Info Team
• July 16, 2026

New app offers real-time voice biofeedback for transgender individuals, speakers, and singers without in-person coaching. Pilot testing underway.

• Thorsten Meyer
• July 13, 2026

McKesson’s media mentions have increased significantly, with 27 mentions in recent coverage, indicating heightened global attention on the healthcare company.

• This Info Team
• July 9, 2026

TaiMed Biologics has received the TFDA drug license collection notice for Trogarz, moving closer to commercial launch in Taiwan.

• This Info Team
• July 8, 2026